Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Leukemia, Myeloid, Acute 19 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Myelodysplastic Syndromes 4 Sarcoma, Myeloid 2 Recurrence 2 Leukemia, Monocytic, Acute 2 Leukemia, Biphenotypic, Acute 2 Leukemia 2 Thyroid Cancer, Papillary 1 Prostatic Neoplasms 1 Philadelphia Chromosome 1 Myeloproliferative Disorders 1 Leukemia, Promyelocytic, Acute 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid 1 Down Syndrome 1 Burkitt Lymphoma 1

Interventions

Magnetic Resonance Spectroscopy 5 trametinib 4 Vemurafenib 4 selpercatinib 3 dabrafenib 3 Specimen Handling 3 entrectinib 2 cobimetinib 2 cabozantinib 2 X-Rays 2 Iodine-131 2 Interviews as Topic 2 tremelimumab 1 tovorafenib 1 spartalizumab 1 pembrolizumab 1 omipalisib 1 lenvatinib 1 gallium Ga 68 dotatate 1 durvalumab 1 copanlisib 1 Whole Body Imaging 1 Transurethral Resection of Prostate 1 Thyrotropin Alfa 1 Surveys and Questionnaires 1 Sodium Iodide 1 Robotic Surgical Procedures 1 Postoperative Period 1 Phantoms, Imaging 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Thyroid Cancer, Papillary × Mitoxantrone × 1 year × Clear all

NCT07354698 2026-01-21

MHI

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 4 Not yet recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡